Cellebrite DI vs Xunlei
Cellebrite DI reported revenue of $476 million in fiscal 2025, about the same as Xunlei's $460 million in fiscal 2025. Cellebrite DI's revenue grew 18.6% in its latest year, and Xunlei's grew 42.5%. Cellebrite DI had an operating margin of 14.0%, against 1.4% at Xunlei. Free cash flow was $160 million at Cellebrite DI and $27 million at Xunlei.
Side by side
| Cellebrite DI | Xunlei | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $476M | $460M |
| Revenue growth | 18.6% | 42.5% |
| Revenue growth a year, last 5 years | 19.5% | 19.8% |
| Gross margin | 84.2% | 47.2% |
| Operating margin | 14.0% | 1.4% |
| Net margin | 16.5% | 227.7% |
| Free cash flow | $160M | $27M |
| Free cash flow margin | 33.7% | 5.9% |
| Return on capital | — | 1.1% |
| Net debt to EBITDA | — | −15.2x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.3% | −0.8% |
| Last close | $11.32 | $3.14 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $5.5 million | — |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cellebrite DIXunlei
Operating margin
Percent of revenue
Cellebrite DIXunlei
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cellebrite DIXunlei
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cellebrite DI and Xunlei pages.